Non-small Cell Lung Cancer Clinical Trials

868 recruitingLast updated: June 19, 2026

There are 868 actively recruiting non-small cell lung cancer clinical trials across 73 countries. Studies span Phase 2, Phase 1, Phase 3, Not Applicable, Phase 4, Early Phase 1. Top locations include Houston, Texas, United States, New York, New York, United States, Guangzhou, Guangdong, China. Updated daily from ClinicalTrials.gov.


Non-small Cell Lung Cancer Trials at a Glance

868 actively recruiting trials for non-small cell lung cancer are listed on ClinicalTrialsFinder across 6 cities in 73 countries. The largest study group is Phase 2 with 382 trials, with the heaviest enrollment activity in Houston, New York, and Guangzhou. Lead sponsors running non-small cell lung cancer studies include AstraZeneca, Hunan Province Tumor Hospital, and Sun Yat-sen University.

Browse non-small cell lung cancer trials by phase

Treatments under study

About Non-small Cell Lung Cancer Clinical Trials

Looking for clinical trials for Non-small Cell Lung Cancer? There are currently 587 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Non-small Cell Lung Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Non-small Cell Lung Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 868 trials

Recruiting

Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols

Non-small Cell Lung CancerMultiple MyelomaLymphoma, Non-Hodgkin+2 more
National Cancer Institute (NCI)500 enrolled1 locationNCT02682667
Recruiting

Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors

Non-small Cell Lung CancerSmall Cell Lung CancerExtrapulmonary Small Cell Cancer+2 more
National Cancer Institute (NCI)2,000 enrolled1 locationNCT02146170
Recruiting
Phase 1Phase 2

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer (NSCLC)Non-small Cell Lung CancerCarcinoma, Non-Small Cell Lung+1 more
National Cancer Institute (NCI)60 enrolled1 locationNCT06694454
Recruiting
Phase 1

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

Colorectal, CancerNon-small Cell Lung CancerPancreatic Ductal Adenocarcinoma
Eli Lilly and Company630 enrolled52 locationsNCT06586515
Recruiting
Phase 1Phase 2

Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expression

Non-small Cell Lung Cancer
Second Affiliated Hospital of Nanchang University45 enrolled1 locationNCT07655622
Recruiting
Phase 1Phase 2

A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors

Non-small Cell Lung CancerAdvanced Solid TumorsSmall Cell Lung Cancer
MediLink Therapeutics (Suzhou) Co., Ltd.260 enrolled1 locationNCT07208773
Recruiting
Phase 3

MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)

Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC400 enrolled56 locationsNCT07431827
Recruiting
Phase 1

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

Triple-Negative Breast CancerEsophageal CancerPancreatic Cancer+11 more
Eli Lilly and Company420 enrolled34 locationsNCT06465069
Recruiting
Phase 2

A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the Brain

Non-small Cell Lung Cancer Metastatic
Memorial Sloan Kettering Cancer Center56 enrolled8 locationsNCT06741085
Recruiting
Phase 2

Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients Undergoing Chemoradiation

Non-small Cell Lung CancerRadiation Induced Lung Injury (RILI)
University Health Network, Toronto150 enrolled1 locationNCT06634056
Recruiting
Phase 2

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer
AbbVie150 enrolled75 locationsNCT06568939
Recruiting
Phase 1

A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

Triple-Negative Breast CancerColorectal, CancerNon-small Cell Lung Cancer+5 more
IDEAYA Biosciences150 enrolled15 locationsNCT07503808
Recruiting
Phase 3

Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets

Non-small Cell Lung CancerBrain Tumor
InSightec30 enrolled11 locationsNCT05317858
Recruiting
Phase 1

Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors

Triple-Negative Breast CancerColorectal, CancerSoft Tissue Sarcoma+3 more
Novartis Pharmaceuticals180 enrolled8 locationsNCT07261631
Recruiting
Phase 1

Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease

MelanomaNon-small Cell Lung CancerMuscle-Invasive Bladder Carcinoma+1 more
Washington University School of Medicine64 enrolled1 locationNCT06529822
Recruiting
Phase 1Phase 2

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Colorectal, CancerColorectal CarcinomaNon-small Cell Lung Cancer+29 more
Institut de Recherches Internationales Servier554 enrolled27 locationsNCT05786924
Recruiting
Phase 1Phase 2

A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

Advanced or Metastatic Non-small Cell Lung Cancer
AstraZeneca152 enrolled103 locationsNCT06996782
Recruiting
Phase 2

A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib

Non-small Cell Lung Cancer
Abbisko Therapeutics Co, Ltd86 enrolled17 locationsNCT07164170
Recruiting
Phase 1

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

Triple-Negative Breast CancerPancreatic CancerNon-small Cell Lung Cancer+4 more
AbbVie694 enrolled46 locationsNCT05005403
Recruiting
Not Applicable

Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung Cancer

Lung AdenocarcinomaCigarette SmokerCurrent Smoker+2 more
Ohio State University Comprehensive Cancer Center3,584 enrolled1 locationNCT03199651